P618: LONG-TERM SAFETY WITH ≥12 MONTHS OF PIRTOBRUTINIB IN RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES

Lignende værker

• S146: GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR (CBTKI) PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY
  af: Jennifer R. Brown, et al.
  Udgivet: (2023-08-01)
• GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY
  af: JR Brown, et al.
  Udgivet: (2023-10-01)
• PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH 2 YEARS OF SURVIVAL FOLLOW-UP
  af: NN Shah, et al.
  Udgivet: (2023-10-01)
• P1100: BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAÏVE MCL (TRIAL IN PROGRESS)
  af: T. A. Eyre, et al.
  Udgivet: (2022-06-01)
• Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study
  af: Nirav N. Shah, et al.
  Udgivet: (2025-12-01)